Compounded vs Pharmaceutical Semaglutide: UK Safety Guide

Compounded semaglutide is a version of the active pharmaceutical ingredient (API) semaglutide that is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk, the company that holds the patent and marketing authorisation for Ozempic and Wegovy.

Compounding is the practice of creating customised medications by combining, mixing, or altering ingredients to meet a specific patient's needs. In the context of semaglutide, compounding pharmacies source the raw semaglutide API (or semaglutide sodium salt) from chemical manufacturers and formulate it into injectable solutions.

Key differences from pharmaceutical semaglutide:

• •Manufacturing: Novo Nordisk manufactures Ozempic and Wegovy in large-scale GMP facilities with extensive quality controls. Compounded versions are prepared in smaller compounding facilities with variable quality standards.
• •Formulation: Pharmaceutical semaglutide uses a specific formulation optimised for stability, bioavailability, and shelf life. Compounded versions may use different excipients, concentrations, and formulation approaches.
• •Form: Compounded semaglutide is typically provided as a multi-dose vial rather than in the pre-filled pen devices used by Ozempic and Wegovy. This requires users to draw up doses manually with syringes.
• •Regulatory oversight: Pharmaceutical products undergo full regulatory review and ongoing batch testing. Compounded products receive significantly less regulatory oversight.
• •Cost: Compounded semaglutide is typically 40–70% cheaper than brand-name products, which is the primary driver of its popularity.

The US context: The compounded semaglutide market exploded in the United States during 2023–2024, when the FDA listed semaglutide on its drug shortage list, which allowed compounding pharmacies to produce copies under Section 503A of the Federal Food, Drug, and Cosmetic Act. This exemption has since been a subject of legal and regulatory dispute.

The regulatory framework for compounded medicines in the UK differs significantly from the US, and understanding these differences is essential.

UK compounding regulations: In the UK, compounding is governed by the Human Medicines Regulations 2012. Licensed compounding (also called "specials" manufacturing) requires a Manufacturer's Specials Licence (MS Licence) from the MHRA. Pharmacies can also compound on a smaller scale under Section 10 exemptions, but this is intended for individual patient prescriptions, not large-scale production.

The legal position of compounded semaglutide in the UK:

• •Semaglutide is a prescription-only medicine (POM) in the UK
• •A doctor can legally prescribe a compounded version if there is a clinical justification (e.g., shortage of the branded product, need for a specific dose not commercially available)
• •The compounding pharmacy must hold appropriate MHRA licensing
• •The prescriber takes clinical responsibility for the compounded product

Key regulatory distinctions from the US:

• •The UK does not have an equivalent of the US "drug shortage" exemption that opened the floodgates for compounded semaglutide in America
• •UK compounding pharmacies operate under tighter regulatory oversight than many US 503A facilities
• •The MHRA has been more cautious about allowing widespread compounding of commercially available medicines
• •Importing compounded semaglutide from overseas (particularly from US compounders) is legally problematic and may be intercepted by MHRA border enforcement

MHRA's stance: The MHRA has not issued a specific public statement about compounded semaglutide as of early 2026, but its general position is clear — compounded versions of commercially available medicines should only be used when there is a genuine clinical need that cannot be met by the licensed product. Routine substitution of Ozempic or Wegovy with a compounded alternative purely for cost savings is not the intended use of compounding provisions.

Practical reality: Despite the regulatory framework, some UK clinics and online services have begun offering compounded semaglutide, often sourced from UK-licensed compounding pharmacies. The regulatory status of these arrangements exists in a grey area that the MHRA may choose to clarify or enforce against in the future.

The quality of compounded semaglutide is the central concern, and it is where the risk-benefit calculation becomes most critical.

API sourcing: The semaglutide active pharmaceutical ingredient used by compounders is typically sourced from third-party chemical manufacturers, primarily in China and India. The quality of these APIs varies significantly. Whilst some manufacturers produce high-purity material under GMP conditions, others operate to lower standards.

Specific quality concerns:

1. Semaglutide salt form: Compounders often use semaglutide sodium salt rather than the base form used in Ozempic/Wegovy. This affects dosing calculations — the salt form has a different molecular weight, and improper conversion can lead to under- or over-dosing.

2. Purity and impurities: Pharmaceutical-grade semaglutide exceeds 99% purity with tightly controlled impurity profiles. Compounded versions may have lower purity and different impurity profiles. Peptide-related impurities (fragments, aggregates) can affect both efficacy and safety.

3. Sterility: Injectable products must be sterile. Pharmaceutical manufacturers validate their sterilisation processes extensively. Compounding pharmacies vary in their sterility assurance procedures. Contaminated injectables can cause serious infections.

4. Stability: Novo Nordisk has invested heavily in formulation research to ensure Ozempic and Wegovy remain stable and potent throughout their shelf life. Compounded formulations may not have undergone equivalent stability testing, meaning the product could degrade faster or less predictably.

5. Endotoxin levels: Bacterial endotoxins in injectable products can cause fever, inflammation, and potentially life-threatening reactions. Pharmaceutical products are rigorously tested; compounded products may not receive the same level of endotoxin testing.

6. Dose accuracy: Pre-filled pens deliver precise, consistent doses. Multi-dose vials require manual drawing up with syringes, which introduces dosing variability — particularly problematic given semaglutide's dose-sensitive effects.

FDA warnings: The FDA has issued multiple warnings about compounded semaglutide products in the US, citing adverse event reports including nausea, vomiting, and hypoglycaemia at higher rates than expected for pharmaceutical semaglutide. Some reports involved products that tested positive for bacterial contamination or contained incorrect doses.

The cost difference is the primary motivation for choosing compounded semaglutide, and it is substantial:

Pharmaceutical semaglutide (private prescription): - Wegovy maintenance dose (2.4mg/week): £220–300/month - Ozempic 1mg/week: £150–250/month - Includes pre-filled pen device with precise dosing

Compounded semaglutide (where available): - Typical cost: £80–150/month - Requires separate syringes for injection - Savings of approximately 40–70% versus branded products

What accounts for the price difference?

1. No R&D cost recovery: Novo Nordisk invested billions in developing, trialling, and bringing semaglutide to market. Their pricing reflects this investment and ongoing pharmacovigilance. Compounders bear none of these costs.

2. API cost: The raw semaglutide ingredient is expensive but constitutes only a fraction of the branded product's price. Compounders source it at market rates and add their formulation and dispensing margin.

3. No device cost: Pre-filled pen devices add significant cost to branded products. Compounded semaglutide in vials eliminates this expense.

4. Lower regulatory overhead: Meeting full GMP and regulatory requirements for a licensed medicine is costly. Compounding operations face lower regulatory compliance costs.

5. No marketing costs: Novo Nordisk's marketing and distribution infrastructure adds to the product cost.

The hidden costs of compounding:

• •Syringes and needles (typically £10–20/month)
• •Potentially more frequent medical monitoring due to dose variability concerns
• •Risk of adverse effects from quality issues, which may incur medical costs
• •No manufacturer-backed pharmacovigilance or adverse event reporting system
• •If the product is ineffective due to quality issues, the money is wasted

The value calculation: Saving £100–150 per month is meaningful, but it must be weighed against the increased risks of using a product with less regulatory oversight and quality assurance. For a medication injected weekly over months or years, the cumulative risk is worth careful consideration.

Regulatory agencies worldwide have raised concerns about compounded semaglutide. Understanding these warnings provides important context for UK consumers:

FDA actions (United States): - The FDA removed semaglutide from the drug shortage list in 2024, which legally should have ended the compounding exemption - Novo Nordisk and the FDA have pursued legal action against compounders continuing to produce semaglutide - The FDA has received adverse event reports associated with compounded semaglutide products, including hospitalisations - The FDA has issued warning letters to compounders selling semaglutide with inadequate quality controls - The agency has emphasised that "compounded semaglutide" and "pharmaceutical semaglutide" are not interchangeable and should not be treated as equivalent

Key FDA concerns: - Products labelled as "semaglutide" may contain the salt form, leading to dosing discrepancies - Some compounded products have failed potency testing, containing significantly more or less semaglutide than stated - Sterility failures have been documented - The clinical efficacy and safety of compounded formulations have not been established through clinical trials

Australian TGA: The Therapeutic Goods Administration in Australia has similarly warned about compounded peptides and tightened regulations around their supply.

Relevance to the UK: Whilst FDA warnings do not directly apply to the UK, they provide data points about the risks associated with compounded semaglutide. The quality issues identified by the FDA — dosing inaccuracies, sterility failures, potency variation — are not US-specific problems. They are inherent risks of compounding a complex peptide outside of full GMP pharmaceutical manufacturing.

The broader lesson: When a regulatory body with the resources and expertise of the FDA raises quality concerns about compounded semaglutide, UK consumers should take note, even though the specific products differ. The underlying manufacturing challenges are the same regardless of jurisdiction.

Based on the available evidence, here are practical recommendations for anyone considering compounded versus pharmaceutical semaglutide in the UK:

1. Pharmaceutical semaglutide is the safer choice. Ozempic and Wegovy have undergone extensive clinical testing, are manufactured to the highest quality standards, and are backed by ongoing pharmacovigilance. If you can access and afford them, they are the recommended option.

2. If considering compounded semaglutide: - Ensure the prescribing clinician is GMC-registered and conducts a proper clinical assessment - Verify that the compounding pharmacy holds an MHRA Manufacturer's Specials Licence - Ask for certificates of analysis confirming purity, potency, and sterility - Understand that you are accepting a higher level of risk than with pharmaceutical products - Report any adverse effects to both your prescriber and the MHRA Yellow Card scheme

3. Be wary of overseas-sourced compounded semaglutide. Products compounded outside the UK, particularly from unregulated suppliers, carry the highest risk. Importing prescription medicines without proper licensing is legally questionable and bypasses UK quality controls.

4. "Research-grade" semaglutide is not compounded semaglutide. Some vendors sell semaglutide labelled as "research use only" — this is a research chemical, not a compounded medicine, and carries even greater risk. Do not confuse the two.

5. Cost savings are not worth serious health risks. A contaminated or incorrectly dosed injectable product can cause genuine harm. The £100–150 monthly saving must be weighed against this reality.

6. Monitor closely. If using any semaglutide product, monitor your response, blood glucose levels, and side effects. Any unexpected or severe side effects should prompt immediate medical evaluation.

7. Stay informed about regulatory changes. The MHRA may issue specific guidance about compounded semaglutide. Monitor MHRA communications and the Yellow Card scheme for emerging safety signals.

*This guide is for educational purposes only. Always consult a qualified healthcare professional before starting any medication, and use licensed pharmaceutical products wherever possible.*